LataMed AI Corp. (OTC: LMED), a healthcare technology company developing digital health infrastructure and AI-supported medical solutions for Latin America, announced that its mobile healthcare application has entered the final stage of development. The company is completing testing, optimization, and deployment preparation ahead of planned availability through the Apple App Store and Google Play.
Management expects to submit the application for distribution shortly, and subject to platform review, it could become available within weeks. This move represents a transition from development to public availability, providing users with a primary mobile access point to the LataMed AI digital healthcare ecosystem. The app aims to offer a convenient interface for accessing supported healthcare services and digital tools, with functionality expected to expand over time.
Potential features include patient-facing tools, healthcare-provider interaction, digital communications, access to medical and wellness information, and healthcare-service coordination. The company believes mobile accessibility is crucial in Latin America, where smartphones are a primary means of accessing digital services for many individuals.
"Our mobile application is now moving from development toward deployment, and we believe we are approaching an important milestone for LataMed AI," said Dr. Kevin Rodan Levy, CEO. "Our team is completing the final stages of testing and preparation, and we currently expect the application to become available through the Apple App Store and Google Play in the coming weeks, subject to the applicable platform review processes."
Dr. Levy added, "Mobile availability is important because it provides a direct connection between users and the digital healthcare ecosystem we are building. Our objective is to create a platform that is practical, accessible, and capable of expanding as we continue introducing additional healthcare services and artificial intelligence-supported tools."
The application is also expected to support the company's longer-term strategy of connecting patients, healthcare professionals, pharmacies, insurers, payment providers, wellness organizations, and other participants in a more integrated digital healthcare environment. LataMed AI continues to develop AI-supported technologies, including CardioAI, PulmoAI, and NeuroAI, as part of its broader strategy. The mobile infrastructure is intended to provide an additional pathway for users and healthcare professionals to interact with supported components of the ecosystem, subject to development, testing, regulatory requirements, and commercial implementation.
The anticipated release is a step toward making LataMed AI's technology accessible to users. Following the initial launch, the company plans to evaluate additional functionality, platform integrations, and user-facing tools for future versions. Updates on submission, availability, and functionality will be provided as milestones are completed.
For more information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
